[HTML][HTML] Long-term real-world outcomes of first-line pembrolizumab monotherapy for metastatic non-small cell lung cancer with≥ 50% expression of programmed cell …
V Velcheti, X Hu, L Yang, MC Pietanza… - Frontiers in …, 2022 - frontiersin.org
Objectives Immune checkpoint inhibitors (ICIs) of programmed cell death 1/programmed cell
death ligand 1 (PD-1/PD-L1) have been rapidly adopted in US clinical practice for first-line …
death ligand 1 (PD-1/PD-L1) have been rapidly adopted in US clinical practice for first-line …
Real-world efficacy of first-line pembrolizumab in patients with advanced or recurrent non–small-cell lung cancer and high PD-L1 tumor expression
Y Tambo, T Sone, K Shibata, K Nishi, H Shirasaki… - Clinical Lung Cancer, 2020 - Elsevier
Background In clinical trials, first-line treatment with pembrolizumab improved overall
survival (OS) in patients with advanced non–small-cell lung cancer (NSCLC) with a …
survival (OS) in patients with advanced non–small-cell lung cancer (NSCLC) with a …
Pembrolizumab plus ipilimumab or placebo for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%: randomized, double-blind phase III …
M Boyer, MAN Şendur, D Rodríguez-Abreu… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE Pembrolizumab monotherapy is standard first-line therapy for metastatic non–
small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion …
small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) tumor proportion …
Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study
PURPOSE Pembrolizumab monotherapy has demonstrated durable antitumor activity in
advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer …
advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer …
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort …
M Tamiya, A Tamiya, K Hosoya, Y Taniguchi… - Investigational new …, 2019 - Springer
Objectives As first line therapy, pembrolizumab provides longer progression free survival
(PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD …
(PFS) and overall survival (OS) than platinum doublets in programmed death ligand 1 (PD …
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50%
Background Single-agent pembrolizumab represents the standard first-line option for
metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death …
metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death …
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled …
H Borghaei, CJ Langer, L Paz‐Ares… - Cancer, 2020 - Wiley Online Library
Background Pembrolizumab plus platinum‐based chemotherapy has demonstrated
improved clinical outcomes over chemotherapy alone in patients with previously untreated …
improved clinical outcomes over chemotherapy alone in patients with previously untreated …
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho… - The Lancet, 2019 - thelancet.com
Background First-line pembrolizumab monotherapy improves overall and progression-free
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …
Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%
M Reck, D Rodríguez-Abreu, AG Robinson… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE We report the first 5-year follow-up of any first-line phase III immunotherapy trial
for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials. gov identifier …
for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials. gov identifier …
[HTML][HTML] A changing of the guard: immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer
JM Pacheco, DR Camidge, RC Doebele… - Frontiers in …, 2019 - frontiersin.org
Inhibitory antibodies targeting programmed death protein 1 (PD-1) and programmed death
ligand 1 (PD-L1) have resulted in improved outcomes for many patients with metastatic non …
ligand 1 (PD-L1) have resulted in improved outcomes for many patients with metastatic non …